MMV in partnership: The Eurartesim ® experience

Malaria Journal

Volumn 12, Issue 1, 2013, Pages

  Ubben, David ^a   Poll, Elizabeth M ^a  

^a Medicines for Malaria Venture   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE; ARTESUNATE PLUS MEFLOQUINE; COTECXIN; DIHYDROARTEMISININ PLUS PIPERAQUINE; MOXIFLOXACIN; PLACEBO; UNCLASSIFIED DRUG;

ANTIMALARIAL ACTIVITY; ARTICLE; BODY WEIGHT; CASE STUDY; CLINICAL TRIAL (TOPIC); DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUSTRY; DRUG MARKETING; DRUG TOLERABILITY; ENDEMIC DISEASE; GOOD CLINICAL PRACTICE; GOOD MANUFACTURING PRACTICE; HEALTH CARE DELIVERY; HEALTH CARE SYSTEM; HUMAN; MALARIA; MONOTHERAPY; POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; ARTEMISININS; CAMBODIA; CHILD; CHILD, PRESCHOOL; DRUG APPROVAL; DRUG COMBINATIONS; HUMANS; INFANT; INFANT, NEWBORN; INTERNATIONAL COOPERATION; MALARIA; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; QUINOLINES;

EID: 84879056888     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-12-211     Document Type: Article

References (38)

1. Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. Nayyar GM, Breman JG, Newton PN, Herrington J, Lancet Infect Dis 2012 12 488 496 10.1016/S1473-3099(12)70064-6 22632187
2. WHO, Antimalarial drug combination therapy: report of a WHO technical consultation Geneva: World Health Organization 2001
3. Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria. Denis MB, Davis TME, Hewitt S, Incardona S, Nimol K, Fandeur T, Poravuth Y, Lim C, Socheat D, Clin Infect Dis 2002 35 1469 1476 10.1086/344647 12471565 (Pubitemid 36020689)
4. Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin ®) in Cambodian children and adults with malaria. Karunajeewa H, Lim C, Hung T-Y, Ilett KF, Denis MB, Socheat D, Davis TME, Br J Clin Pharmacol 2003 57 93 99 10.1046/j.1365-2125.2003.01962.x (Pubitemid 38067955)
5. Randomized, controlled dose-optimization studies of dihydroartemisinin- piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. Ashley EA, Krudsood S, Phaiphun L, Srivilairit S, McGready R, Leowattana W, Hutagalung W, Wilairatana P, Brockman A, Looareesuwan S, Nosten F, White NJ, J Infect Dis 2004 190 1773 1782 10.1086/425015 15499533 (Pubitemid 39487822)
6. Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Hien TT, Dolecek C, Mai PP, Dung NT, Truong NT, Thai LH, An DTH, Thanh TT, Stepniewska K, White NJ, Farrar J, Lancet 2004 363 18 22 10.1016/S0140-6736(03)15163-X 14723988 (Pubitemid 38076920)
7. A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Ashley EA, McGready R, Hutagalung R, Phaiphun L, Slight T, Proux S, Thwai KL, Barends M, Looareesuwan S, White NJ, Nosten F, Clin Infect Dis 2005 41 425 432 10.1086/432011 16028147 (Pubitemid 41099632)
8. Efficacy and safety of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in endemic countries: meta-analysis of randomised controlled studies. Naing C, Mak JW, Aung K, Wong JY, Trans R Soc Trop Med Hyg 2013 107 65 73 10.1093/trstmh/trs019 23222952
9. World Health Organization, Global plan for artemisinin resistance containment (GPARC) 2011 [ http://www.who.int/malaria/publications/atoz/ artemisinin-resistance-containment-2011.pdf ]
10. Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. Leang R, Barrette A, Bouth DM, Menard D, Abdur R, Duong S, Ringwald P, Antimicrob Agents Chemother 2013 57 818 826 10.1128/AAC.00686-12 23208711
11. Field observations on the antimalarial piperaquine. Chen L, Qu FY, Zhou YC, Chin Med J (Engl) 1982 95 281 286 (Pubitemid 12062202)
12. Antimalarial compounds: from bench to bedside. Olliaro PL, Taylor WRJ, J Exp Biol 2003 206 3753 3759 10.1242/jeb.00653 14506210 (Pubitemid 37365457)
13. Piperaquine: a resurgent antimalarial drug. Davis TM, Hung TY, Sim IK, Karunajeewa HA, Ilett KF, Drugs 2005 65 75 87 10.2165/00003495-200565010-00004 16335861
14. A field trial of efficacy of CV8 in treatment of uncomplicated falciparum malaria. Tip NQ, Trung TN, Tan TV, Phuc NT, J Malar Parasit Dis Control 2001 4 45 51
15. CV8, a new combination of dihydroartemisinin, piperaquine, trimethoprim and primaquine, compared with atovaquone-proguanil against falciparum malaria in Vietnam. Giao PT, de Vries PJ, Hung LQ, Binh TQ, Nam NV, Kager PA, Trop Med Int Health 2004 9 209 216 10.1046/j.1365-3156.2003.01180.x 15040557 (Pubitemid 38250807)
16. China's new drug GMP: higher standards, new compliance philosophy. Li L, Update: Food and Drug Law, Regulation and Education 2011 [ http://www.fdli.org/ resources/resources-list-view/drugs,/press-releases,policy-forums, update-magazine,whitepapers,/page/7 ] 19649267
17. Case study of medicines for malaria venture. Kaminski M, Int Affairs Rev Winter 2011 XX 1 [ http://www.iar-gwu.org/sites/default/files/articlepdfs/ Morgan%20Kaminski%20-%20MMV.pdf ]
18. WHO, Guidelines for the treatment of malaria Geneva: World Health Organization 2006
19. An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia. Valecha N, Phyo AP, Mayxay M, Newton PN, Krudsood S, Keomany S, Khanthavong M, Pongvongsa T, Ruangveerayuth R, Uthaisil C, Ubben D, Duparc S, Bacchieri A, Corsi M, Rao BHK, Bhattacharya PC, Dubhashi N, Ghosh SK, Dev V, Kumar A, Pukittayakamee S, PLoS One 2010 5 11880 10.1371/journal.pone.0011880 20689583
20. An open, randomized comparison of artesunate plus mefloquine vs. dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in the Lao People's Democratic Republic (Laos). Mayxay M, Thongpraseuth V, Khanthavong M, Lindega N, Barends M, Keola S, Pongvongsa T, Phompida S, Phetsouvanh R, Stepniewska K, White NJ, Newton PN, Trop Med Int Health 2006 11 1157 1165 10.1111/j.1365-3156.2006.01671.x 16903879 (Pubitemid 44125705)
21. Dihydroartemisinin/Piperaquine: a review of its use in the treatment of uncomplicated Plasmodium falciparum malaria. Keating GM, Drugs 2012 72 937 961 10.2165/11203910-000000000-00000 22515619
22. Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. Bassat Q, Mulenga M, Tinto H, Piola P, Borrmann S, Menendez C, Nambozi M, Vale I, Nabasumba C, Sasi P, Bacchieri A, Corsi M, Ubben D, Talisuna A, D'Alessandro U, PLoS One 2009 4 7871 10.1371/journal.pone.0007871 19936217
23. Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Nambozi M, van Geertruyden JP, Hachizovu S, Chaponda M, Mukwamataba D, Mulenga M, Ubben D, D'Alessandro U, Malar J 2011 10 50 10.1186/1475-2875-10-50 21352609
24. European Medicines Agency, European medicines agency eurartesim assessment report, 23 June 2011 European Medicines Agency 2011
25. Therapeutic efficacy and safety of dihydroartemisinin-piperaquine versus artesunate-mefloquine in uncomplicated Plasmodium falciparum malaria in India. Gargano N, Ubben D, Tommasini S, Bacchieri A, Corsi M, Bhattacharyya PC, Rao BH, Dubashi N, Dev V, Ghosh SK, Kumar A, Srivastava B, Valecha N, Malar J 2012 11 233 10.1186/1475-2875-11-233 22818552
26. Efficacy and safety of dihydroartemisinin-piperaquine. Myint HY, Ashley EA, Day NPJ, Nosten F, White NJ, Trans R Soc Trop Med Hyg 2007 101 858 866 10.1016/j.trstmh.2007.05.018 17659311 (Pubitemid 47091464)
27. European Medicines Agency, Article 10A of Directive 2001/83/EC of the European parliament and of the Council of 6 November 2001 on the community code relating to medicinal products for human use [ http://www.emea.europa.eu/docs/ en-GB/document-library/Regulatory-and-procedural-guideline/2009/10/WC500004481. pdf ]
28. European Commission Enterprise and Industry Directorate-General, Guidance on a new therapeutic indication for a well-established substance Brussels: The European Commission 2007
29. European Medicines Agency, Eurartesim summary of product characteristics 2011 [ http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/ medicines/001199/human-med-001450.jsp&mid=WC0b01ac058001d124 ]
30. Relationship between treatment-seeking behaviour and artemisinin drug quality in Ghana. Klein EY, Lewis IA, Jung C, Llinás M, Levin SA, Malar J 2012 11 110 10.1186/1475-2875-11-110 22482747
31. In vitro cardiovascular effects of dihydroartemisin-piperaquine combination compared with other antimalarials. Borsini F, Crumb W, Pace S, Ubben D, Wible B, Yan GX, Funck-Brentano C, Antimicrob Agents Chemother 2012 56 3261 3270 10.1128/AAC.05688-11 22391528
32. Benefits of using multiple first-line therapies against malaria. Boni MF, Smith DL, Laxminarayan R, Proc Natl Acad Sci USA 2008 105 14216 14221 10.1073/pnas.0804628105 18780786
33. Prospective strategies to delay the evolution of anti-malarial drug resistance: weighing the uncertainty. Smith DL, Klein EY, McKenzie FE, Laxminarayan R, Malar J 2010 9 217 10.1186/1475-2875-9-217 20653960
34. Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria. Sinclair D, Gogtay N, Brand F, Olliaro P, Cochrane Database Syst Rev 2011 7 D008492 21735431
35. Chemotherapeutic strategies for reducing transmission of Plasmodium vivax malaria. Douglas NM, John GK, von Seidlein L, Anstey NM, Price RN, Adv Parasitol 2012 80 271 300 23199490
36. Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia. Sutanto I, Tjahjono B, Basri H, Taylor WR, Putri FA, Meilia RA, Setiabudy R, Nurleila S, Ekawati LL, Elyazar I, Farrar J, Sudoyo H, Baird JK, Antimicrob Agents Chemother 2013 57 1128 1135 10.1128/AAC.01879-12 23254437
37. The Global Fund, Fact sheet, ACT prices under the affordable medicines facility-malaria 2013 [ http://www.theglobalfund.org/en/amfm/ ]
38. Assessing the effect of the recommended dihydroartemisinin-piperaquine dosing regimen on the risk of treatment failure in patients diagnosed with uncomplicated Plasmodium falciparum malaria. Price RN (on behalf of The WWARN DHA-PQP Dose Impact Study Group), Am J Trop Med Hyg 2012 166 551